Urovant Sciences Competitors and Similar CompaniesClear all
Urovant Sciences's competitors and similar companies include Novartis, Pfizer, Takeda, Astellas Pharma and Kymera Therapeutics.
 Urovant Sciences Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  Kymera Therapeutics Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. | |
Founding Date | Founding Date 2016 | Founding Date 1996 | Founding Date 1849 | Founding Date 1781 | Founding Date 1923 | Founding Date 2017 |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||
Locations | Locations Irvine, US HQ Basel, CH | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Watertown, US HQ Cambridge, US | |
Employees | Employees 3950% increase | Employees 75,883 | Employees 81,0008% decrease | Employees 47,4554% decrease | Employees 14,754 | Employees 207 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) 43.7 b | Valuation ($) 20.8 b | Valuation ($) 3.1 b |
Financial | ||||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) ¥2.1t (FY, 2026) | Revenue (est.) $39.2m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $8.4b (FY, 2025) | Cost of goods $16.1b (FY, 2025) | Cost of goods ¥818.8b (FY, 2025) | Cost of goods ¥213.8b (FY, 2026) | Cost of goods $39.2m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $49.8b (FY, 2025) | Gross profit $46.5b (FY, 2025) | Gross profit ¥3.8t (FY, 2025) | Gross profit ¥2t (FY, 2026) | Gross profit N/A |
Net income | Net income ($146.7m) (FY, 2020) | Net income $14b (FY, 2025) | Net income $7.8b (FY, 2025) | Net income ¥108.1b (FY, 2025) | Net income ¥291.6b (FY, 2026) | Net income ($311.4m) (FY, 2025) |
Operating ⚠ | ||||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 51 (FY, 2024) | Phase I Trials Products 2 (May, 2025) | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 27 (FY, 2024) | Phase II Trials Products 10 (May, 2025) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products 17 (May, 2025) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) N/A |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 5 (FY, 2024) | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A |
Funding | ||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised $ 197m |
For sources of this data, please see the company profile
View Company Profiles
Novartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyPfizer
HQ
New York, US
Employees
81,000↓ 8% decrease
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View companyAstellas Pharma
HQ
Tokyo, JP
Employees
14,754
Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
View company